Despite the lack of consensus on the prognostic role of VEGFR1 in tumor, the high surface levels of VEGFR1 that we observe early in tumor development suggest that antiangiogenic therapies may need to be tuned to respond to the dynamics of the progressing tumor microenvironment. The gene discussed is FLT1; the disease is neoplasm.